Humidified high-flow nasal oxygen utilization in patients with cancer at Memorial Sloan-Kettering Cancer Center Journal Article
| Authors: | Epstein, A. S.; Hartridge-Lambert, S. K.; Ramaker, J. S.; Voigt, L. P.; Portlock, C. S. |
| Article Title: | Humidified high-flow nasal oxygen utilization in patients with cancer at Memorial Sloan-Kettering Cancer Center |
| Abstract: | Background: Respiratory signs and symptoms are commonly encountered by physicians who care for cancer patients. Supplemental oxygen (SOx) has long been used for treatment of hypoxic respiratory insufficiency, but data reveal mixed efficacy results. The use and outcome patterns of technologically advanced oxygen delivery devices, such as humidified high-flow nasal oxygen (HHFNOx), are incompletely understood. Methods: Institutional database search of the number of patient cases in which the current HHFNOx device was used, and abstraction of 183 patient medical records for usage characteristics. Results: Patients have been treated with HHFNOx at Memorial Sloan Kettering Cancer Center (MSKCC) since 2008. Of the 183 patients randomly selected for our study, 72% received HHFNOx in the intensive care unit (ICU) because of hypoxia. Patients usually improved (41%) or remained stable (44%) while on the device, whereas 15% declined. At study completion, 45% of patients were living, and 55% had died. The median time on HHFNOx was 3 days (range: 1-27). A do not resuscitate (DNR) order was present in 101 (55%) patients, either before (12%) or after (43%) device utilization. The majority (78%) of these 101 patients died at MSKCC. Conclusion: Dyspnea is a common and important symptom in cancer patients for which SOx traditionally has had no clear basis except in select cases of hypoxia and patient preference. Our institutional experience with HHFNOx contributes to the understanding of the applications and challenges surrounding the use of new medical devices in the cancer population. Physiologic and quality-of-life benefits of HHFNOx compared with traditional oxygen delivery methods should be studied prospectively. © 2011, Mary Ann Liebert, Inc. |
| Keywords: | adult; aged; major clinical study; cancer patient; outcome assessment; oxygen therapy; retrospective study; cancer mortality; hypoxia; intensive care; cancer center; medical record; oxygen consumption; treatment refusal; oxygen saturation; intubation; nasogastric tube; positive end expiratory pressure; ambient air; face tent oxygen device; humidified high flow nasal oxygen delivery device; nonrebreather oxygen mask; nose irritation; oxygen delivery device; oxygen mask |
| Journal Title: | Journal of Palliative Medicine |
| Volume: | 14 |
| Issue: | 7 |
| ISSN: | 1096-6218 |
| Publisher: | Mary Ann Liebert, Inc |
| Date Published: | 2011-06-23 |
| Start Page: | 835 |
| End Page: | 839 |
| Language: | English |
| DOI: | 10.1089/jpm.2011.0005 |
| PROVIDER: | scopus |
| PUBMED: | 21599530 |
| PMCID: | PMC5586152 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 17 August 2011" - "CODEN: JPAMF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work